Abstract:Alzheimer's disease is a neurodegenerative disease that accounts for most of the 50-million dementia cases worldwide in 2018. A large amount of evidence supports the amyloid cascade hypothesis, which states that amyloid-beta accumulation triggers tau hyperphosphorylation and aggregation in form of neurofibrillary tangles, and these aggregates lead to inflammation, synaptic impairment, neuronal loss, and thus to cognitive decline and behavioral abnormalities. The poor correlation found between cognitive decline and amyloid plaques, have led the scientific community to question whether amyloid-beta accumulation is actually triggering neurodegeneration in Alzheimer's disease. The occurrence of tau neurofibrillary tangles better correlates to neuronal loss and clinical symptoms and, although amyloid-beta may initiate the cascade of events, tau impairment is likely the effector molecule of neurodegeneration. Recently, it has been shown that amyloid-beta and tau cooperatively work to impair transcription of genes involved in synaptic function and, more importantly, that downregulation of tau partially reverses transcriptional perturbations. Despite mounting evidence points to an interplay between amyloid-beta and tau, some factors could independently affect both pathologies. Thus, the dual pathway hypothesis, which states that there are common upstream triggers causing both amyloid-beta and tau abnormalities has been proposed. Among others, the immune system seems to be strongly involved in amyloid-beta and tau pathologies. Other factors, as the apolipoprotein E ε4 isoform has been suggested to act as a link between amyloid-beta and tau hyperphosphorylation. Interestingly, amyloid-beta-immunotherapy reduces not only amyloid-beta but also tau levels in animal models and in clinical trials. Likewise, it has been shown that tau-immunotherapy also reduces amyloid-beta levels. Thus, even though amyloid-beta immunotherapy is more advanced than tau-immunotherapy, combined amyloid-beta and tau-directed therapies at early stages of the disease have recently been proposed as a strategy to stop the progression of Alzheimer's disease.

Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease

Synergy between amyloid-β and tau in Alzheimer’s disease

Interaction Between A Beta And Tau In The Pathogenesis Of Alzheimer'S Disease

The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease

Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease

Amyloid-beta and tau protein beyond Alzheimer’s disease

Understanding the complex interplay between tau, amyloid and the network in the spatiotemporal progression of Alzheimer’s Disease

Interactions Between Α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders

Amyloid-β and Tau in Alzheimer's Disease

Possible Mechanisms of Tau Spread and Toxicity in Alzheimer's Disease

Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer's disease.

Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks

Possible Mechanisms of Tau Spread and Toxicity in Alzheimer’s Disease

Amyloid-β-independent regulators of tau pathology in Alzheimer disease

Interactions of pathological proteins in neurodegenerative diseases

Amyloid-β Plaques Enhance Alzheimer's Brain Tau-Seeded Pathologies by Facilitating Neuritic Plaque Tau Aggregation

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Tau Protein and Tauopathies: Exploring Tau Protein‐Protein and Microtubule Interactions, Cross‐Interactions and Therapeutic Strategies.